Login to Your Account



Amgen win with Imlygic opens door for oncolytic strategies

By Randy Osborne
Staff Writer

Wednesday, October 28, 2015

Oncolytics Biotech Inc. CEO Brad Thompson said that the FDA's approval of the first oncolytic virus agent, Amgen Inc.'s Imlygic for melanoma, should make raising capital easier for his firm.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription